Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 16/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | IRF3 | Q14653 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL29080462 | 1.00 | STING1 (0.56) | STING1CYP3A4IRF3ATM | |
| Bromide SCHEMBL30615794 | 1.00 | STING1 (0.56) | STING1CYP3A4IRF3ATM | |
| SCHEMBL26772068 | 0.99 | STING1 (0.57) | STING1CYP3A4IRF3ATM | |
| SCHEMBL22925517 | 0.92 | STING1 (0.65) | STING1CYP3A4 | |
| SCHEMBL22121522 | 0.92 | STING1 (0.65) | STING1CYP3A4 | |
| SCHEMBL22121394 | 0.82 | KDM4E (0.47) | STING1CYP3A4 | |
| SCHEMBL23077541 | 0.82 | STING1 (0.57) | STING1CYP3A4 | |
| SCHEMBL23095398 | 0.81 | STING1 (0.54) | STING1CYP3A4 | |
| SCHEMBL29437070 | 0.81 | STING1 (0.54) | STING1CYP3A4 | |
| SCHEMBL25098724 | 0.81 | STING1 (0.68) | STING1CYP3A4ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255981-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | SEAGEN INC (US) | 2025-08-14 | — | — | US | disclosed |
| EP-4518905-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | Seagen Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20240123079-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | SEAGEN INC. | 2024-04-18 | — | — | US | disclosed |
| EP-4277904-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | Seagen Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023215740-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | SEAGEN INC. (US) | 2023-11-09 | — | — | WO | disclosed |
| WO-2022155518-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | SEAGEN INC. (US) | 2022-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240123079-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | CD47, CD22, FCGR2A | STING1 1440/4885CYP3A4 2740/4885IRF3 228/4885 |
| US-20250255981-A1 | IMMUNOMODULATORY ANTIBODY-DRUG CONJUGATES | CD47, CD22, FCGR2A | STING1 1440/4885CYP3A4 2740/4885IRF3 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.